<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138991</url>
  </required_header>
  <id_info>
    <org_study_id>21466</org_study_id>
    <secondary_id>NCI-2021-11335</secondary_id>
    <secondary_id>21466</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>R21CA261797</secondary_id>
    <nct_id>NCT05138991</nct_id>
  </id_info>
  <brief_title>Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors</brief_title>
  <official_title>Assessment of the Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the reproducibility and accuracy of a new portable system that&#xD;
      may detect early cardiac dysfunction (Vivio) at home and in the clinic to currently available&#xD;
      screening tests for heart failure including echocardiogram (echo) and cardiovascular magnetic&#xD;
      resonance (CMR). The Vivio system may help detect cardiac dysfunction earlier than other&#xD;
      available screening tests because it can be self-administered outside of the clinic. This&#xD;
      study aims to test the accuracy and practicality of two new components of the Vivio system in&#xD;
      the clinic setting and at home.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Validate the accuracy of ejection fraction (EF), as measured using Vivio, in the clinical&#xD;
      setting, and determining reproducibility at home.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      1. Determine the cost-effectiveness of Vivio-based screening in the clinic setting and at&#xD;
      home.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo a one time assessment of cardiac function by echocardiogram (echo),&#xD;
      cardiovascular magnetic resonance (CMR), and the Vivio system in the clinic over 4-6 hours,&#xD;
      and then undergo one at home assessment 1-5 days later using the Vivio system by themselves.&#xD;
      Patients also complete questionnaires at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of ejection fraction (EF) in the clinic setting, and determine its reproducibility at home.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will compare EF across the three diagnostic platforms and will generate Bland-Altman plots to evaluate agreement between echo and cardiovascular magnetic resonance (CMR), Vivio and CMR, and echo and the Vivio system. The distribution of the difference between two screening approaches will be checked for normality, and 1-sample t-test will be used to test if the mean difference varies from 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of Vivio-based screening in the clinic setting and at home</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will apply the sensitivity and specificity of echo, CMR, and the Vivio system (clinic, home-based) to compare the number of asymptomatic cardiac dysfunction cases identified via each method. Screening costs for echo and CMR, including costs of clinical services, will be obtained from the 2020 Centers for Medicare &amp; Medicaid Services (CMS).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Screening (echo, CMR, Vivio)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo a one time assessment of cardiac function by echo, CMR, and the Vivio system in the clinic over 4-6 hours, and then undergo one at home assessment 1-5 days later using the Vivio system by themselves. Patients also complete questionnaires at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiogram Recording</intervention_name>
    <description>Undergo assessment via echo</description>
    <arm_group_label>Screening (echo, CMR, Vivio)</arm_group_label>
    <other_name>Echocardiogram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Screening (echo, CMR, Vivio)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stress Cardiac Magnetic Resonance Imaging</intervention_name>
    <description>Undergo assessment via CMR</description>
    <arm_group_label>Screening (echo, CMR, Vivio)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wireless Synchronized Cardiac Function Monitoring Device</intervention_name>
    <description>Undergo assessment via Vivio</description>
    <arm_group_label>Screening (echo, CMR, Vivio)</arm_group_label>
    <other_name>Vivio</other_name>
    <other_name>Vivio System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously enrolled in IRB# 14154.&#xD;
&#xD;
          -  Able to understand and sign the study specific informed consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants cannot be actively receiving cancer-directed therapy.&#xD;
&#xD;
          -  Standard exclusion criteria for CMR imaging will be incorporated, and these include:&#xD;
             implanted pacemaker or defibrillator, insulin pump, cochlear implant, central nervous&#xD;
             system aneurismal clips, implanted neural stimulator, ocular foreign body (metal),&#xD;
             other implanted medical devices (e.g.: drug infusion ports).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saro H Armenian</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Saro H. Armenian</last_name>
      <phone>626-218-7320</phone>
      <email>sarmenian@coh.org</email>
    </contact>
    <investigator>
      <last_name>Saro H. Armenian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

